Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations

Brian D. Lehmann, Timothy M. Shaver, Douglas B. Johnson, Zhu Li, Paula I. Gonzalez-Ericsson, Violeta Sánchez, Yu Shyr, Melinda E. Sanders, Jennifer A. Pietenpol

研究成果: Article同行評審

4 引文 斯高帕斯(Scopus)


Melanomas are characterized by driver and loss-of-function mutations that promote mitogen-activated protein kinase (MAPK) signaling. MEK inhibitors are approved for use in BRAF-mutated melanoma; however, early-phase clinical trials show occasional responses in driver-negative melanoma, suggesting other alterations conferringMAPK/ERK dependency. To identify additional structural alterations in melanoma, we evaluated RNA-Seq from a set of known MAPK/ERK regulators using a novel population-based algorithm in The Cancer Genome Atlas (TCGA). We identified recurrent MAP3K8 rearrangements in 1.7%ofmelanomas in TCGA, occurring inmore than 15% of tumors without known driver mutations (BRAF, NRAS, KIT, GNAQ, GNA11, and NF1). Using an independent tumor set, we validated a similar rearrangement frequency by FISH. MAP3K8-rearranged melanomas exhibit a low mutational burden and absence of typical UV-mutational patterns. We identified two melanoma cell lines that harbor endogenous truncatingMAP3K8 rearrangements that demonstrate exquisite dependency. Rearrangement and amplification of the MAP3K8 locus in melanoma cells result in increased levels of a truncated, active MAP3K8 protein; oncogenic dependency on the aberrant MAP3K8; and a concomitant resistance to BRAF inhibition and sensitivity to MEK or ERK1/2 inhibition. Our findings reveal and biochemically characterize targetable oncogenic MAP3K8 truncating rearrangements in driver mutation- negative melanoma, and provide insight to therapeutic approaches for patients with these tumors. These data provide rationale for using MEK or ERK inhibitors in a subset of drivernegative, MAPK/ERK-dependent melanomas harboring truncating MAP3K8 rearrangements.

頁(從 - 到)1842-1853
期刊Molecular Cancer Research
出版狀態Published - 2019

All Science Journal Classification (ASJC) codes

  • 分子生物學
  • 腫瘤科
  • 癌症研究


深入研究「Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations」主題。共同形成了獨特的指紋。